NO2972360T3 - - Google Patents

Info

Publication number
NO2972360T3
NO2972360T3 NO14721647A NO14721647A NO2972360T3 NO 2972360 T3 NO2972360 T3 NO 2972360T3 NO 14721647 A NO14721647 A NO 14721647A NO 14721647 A NO14721647 A NO 14721647A NO 2972360 T3 NO2972360 T3 NO 2972360T3
Authority
NO
Norway
Application number
NO14721647A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2972360T3 publication Critical patent/NO2972360T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO14721647A 2012-10-03 2014-03-14 NO2972360T3 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261709282P 2012-10-03 2012-10-03

Publications (1)

Publication Number Publication Date
NO2972360T3 true NO2972360T3 (hr) 2018-08-04

Family

ID=50435137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14721647A NO2972360T3 (hr) 2012-10-03 2014-03-14

Country Status (19)

Country Link
US (1) US9303086B2 (hr)
EP (1) EP2905335B1 (hr)
JP (1) JP6280040B2 (hr)
KR (1) KR102149565B1 (hr)
CN (1) CN104704119B (hr)
AU (1) AU2013325443B2 (hr)
CA (1) CA2886772C (hr)
CY (1) CY1120063T1 (hr)
DK (1) DK2905335T3 (hr)
ES (1) ES2665341T3 (hr)
HR (1) HRP20180685T1 (hr)
HU (1) HUE037274T2 (hr)
LT (1) LT2905335T (hr)
NO (1) NO2972360T3 (hr)
PL (1) PL2905335T3 (hr)
PT (1) PT2905335T (hr)
RS (1) RS57120B1 (hr)
SI (1) SI2905335T1 (hr)
WO (1) WO2014054820A1 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101619862B1 (ko) * 2014-09-30 2016-05-12 주식회사 녹십자 간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법
HRP20211640T1 (hr) 2017-02-08 2022-02-04 Adc Therapeutics Sa Konjugati pirolobenzodiazepin - protutijelo
WO2019050362A2 (ko) 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
CN113660954A (zh) * 2019-04-01 2021-11-16 凯奥目生物科学株式会社 癌症治疗用药物
CA3198077A1 (en) 2020-10-05 2022-04-14 Chiome Bioscience Inc. Medicine for treating cancer
CN117279929A (zh) 2021-05-10 2023-12-22 凯奥目生物科学株式会社 抗体组合物的纯化方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0605522B1 (en) * 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH08509358A (ja) 1992-12-11 1996-10-08 アメリカ合衆国 神経内分泌腫瘍で発現されるδ様遺伝子
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP2001269174A (ja) 2000-03-24 2001-10-02 Kirin Brewery Co Ltd 骨髄異形成症候群(mds)の検出方法及びmdsの治療剤
US20030185815A1 (en) 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
EP1421179A1 (en) 2001-08-24 2004-05-26 Nsgene A/S Isolation of cells from neural cell populations using antibodies to fa1/dlk1
CN102659946A (zh) * 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
AU2003215525A1 (en) 2002-03-21 2003-10-08 Nsgene A/S Detection and isolation of cell populations from muscle using antibodies to fa1/dlk1
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ES2382987T3 (es) 2003-11-28 2012-06-15 Kanagawa Academy Of Science And Technology Método de detección de cáncer de hígado, diagnóstico de cáncer de hígado y curación del cáncer
CA2669731C (en) 2006-11-10 2016-01-19 Livtech Inc. Anti-human dlk-1 antibody showing anti-tumor activity in vivo
WO2009116670A1 (ja) 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
EP2848632B1 (en) * 2010-02-23 2019-07-10 Sanofi Human igg1 fc with improved cdc and adcc activity
EP2566517B1 (en) * 2010-05-04 2018-10-24 Five Prime Therapeutics, Inc. Antibodies that bind csf1r

Also Published As

Publication number Publication date
JP6280040B2 (ja) 2018-02-14
ES2665341T3 (es) 2018-04-25
SI2905335T1 (en) 2018-04-30
JPWO2014054820A1 (ja) 2016-08-25
WO2014054820A1 (ja) 2014-04-10
KR102149565B1 (ko) 2020-08-28
US9303086B2 (en) 2016-04-05
AU2013325443A1 (en) 2015-04-09
EP2905335A1 (en) 2015-08-12
CN104704119A (zh) 2015-06-10
US20140193432A1 (en) 2014-07-10
CN104704119B (zh) 2017-09-05
PT2905335T (pt) 2018-03-12
EP2905335A4 (en) 2016-05-18
DK2905335T3 (en) 2018-03-12
HRP20180685T1 (hr) 2018-06-01
CY1120063T1 (el) 2018-12-12
HUE037274T2 (hu) 2018-08-28
RS57120B1 (sr) 2018-06-29
LT2905335T (lt) 2018-04-10
PL2905335T3 (pl) 2018-06-29
EP2905335B1 (en) 2018-01-31
AU2013325443B2 (en) 2019-01-31
CA2886772A1 (en) 2014-04-10
CA2886772C (en) 2021-01-12
KR20150060761A (ko) 2015-06-03

Similar Documents

Publication Publication Date Title
BR112014021579A2 (hr)
BR112014017635A2 (hr)
BR112014017614A2 (hr)
BR112014017592A2 (hr)
BR112014019461A2 (hr)
BR112014019862A2 (hr)
BR112014017607A2 (hr)
BR112013027865A2 (hr)
BR112014017634A2 (hr)
BR112014017609A2 (hr)
BR112014020104A2 (hr)
BR112014017647A2 (hr)
BR112014017588A2 (hr)
BR112014013184A8 (hr)
BR112014017630A2 (hr)
BR112014017627A2 (hr)
BR112014017631A2 (hr)
BR112014017636A2 (hr)
NO2972360T3 (hr)
BR112014017600A2 (hr)
BR112014017596A2 (hr)
BR112014018917A2 (hr)
BR112014017591A2 (hr)
BR112014017589A2 (hr)
BR112014017632A2 (hr)